Effects of Ondansetron on Hemodynamic Changes After Spinal Anesthesia in Geriatric Urologic Surgery
Summary
This prospective observational study (NCT07551219) registered April 24, 2026 evaluates ondansetron, a 5-HT3 receptor antagonist, for attenuating spinal anesthesia-induced hemodynamic instability in geriatric patients undergoing urologic surgery. The study examines whether ondansetron can reduce the incidence of hypotension, bradycardia, and vasopressor requirements during the intraoperative period. Conditions studied include hypotension during surgery, bradycardia, and spinal anesthesia-induced hemodynamic changes.
“Ondansetron, a 5-HT3 receptor antagonist commonly used for the prevention of postoperative nausea and vomiting, has been suggested to attenuate spinal anesthesia-induced hemodynamic instability by modulating vagal reflexes.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This clinical trial registry entry documents a prospective observational study (NCT07551219) examining whether ondansetron attenuates spinal anesthesia-induced hypotension and bradycardia in elderly urologic surgery patients. The study recorded intraoperative hemodynamic parameters and assessed vasopressor requirements. No regulatory compliance obligations are created by this study registration.
For healthcare providers and clinical investigators, this study registration signals emerging research into ondansetron's off-label use for hemodynamic stabilization. Anesthesiologists and urologic surgeons at geriatric care centers should be aware that 5-HT3 receptor antagonism is under investigation as a potential intervention for age-related susceptibility to spinal anesthesia complications.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Effects of Ondansetron on Hemodynamic Changes After Spinal Anesthesia in Geriatric Urologic Surgery
Observational NCT07551219 Kind: OBSERVATIONAL Apr 24, 2026
Abstract
Spinal anesthesia is frequently used in urologic surgery in geriatric patients; however, it may cause significant hemodynamic changes such as hypotension and bradycardia. These changes can be more pronounced in elderly patients due to age-related physiological alterations. Ondansetron, a 5-HT3 receptor antagonist commonly used for the prevention of postoperative nausea and vomiting, has been suggested to attenuate spinal anesthesia-induced hemodynamic instability by modulating vagal reflexes.
This prospective observational study aimed to evaluate the effects of ondansetron on hemodynamic changes following spinal anesthesia in geriatric patients undergoing urologic surgery. Hemodynamic parameters were recorded during the intraoperative period, and the incidence of hypotension, bradycardia, and vasopressor requirements were assessed.
Conditions: Hypotension, Bradycardia, Hypotension During Surgery, Spinal Anesthesia Induced Hemodynamic Change
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.